INVESTOR ALERT: Brower Piven Encourages Shareholders Who Have Losses In Excess Of $100,000 From Investment In Insmed Incorpor...
27 Juillet 2016 - 2:10AM
Business Wire
The securities litigation law firm of Brower Piven, A
Professional Corporation, announces that a class action lawsuit has
been commenced in the United States District Court for the District
of New Jersey on behalf of purchasers of Insmed Incorporated
(Nasdaq: INSM) (“Insmed” or the “Company”) securities during the
period between March 18, 2013 and June 8, 2016, inclusive (the
“Class Period”). Investors who wish to become proactively involved
in the litigation have until September 13, 2016 to seek appointment
as lead plaintiff.
If you wish to choose counsel to represent you and the Class,
you must apply to be appointed lead plaintiff and be selected by
the Court. The lead plaintiff will direct the litigation and
participate in important decisions including whether to accept a
settlement for the Class in the action. The lead plaintiff will be
selected from among applicants claiming the largest loss from
investment in Insmed securities during the Class Period. Members of
the Class will be represented by the lead plaintiff and counsel
chosen by the lead plaintiff. No class has yet been certified in
the above action.
The complaint accuses the defendants of violations of the
Securities Exchange Act of 1934 by virtue of the defendants’
failure to disclose during the Class Period that the data on which
Insmed’s European marketing authorization application (“MAA”)
relied for Arikayce, was not likely to support approval by the
European Medicines Agency (“EMA”) for the treatment of NTM lung
disease, therefore making Arikayce’s approval by the EMA for the
treatment of NTM lung disease and subsequent commercialization in
Europe less likely and/or imminent than Insmed had led investors to
believe.
According to the complaint, following the June 8, 2016
revelation that Insmed had withdrawn its MAA from the EMA for
Arikayce for the treatment of NTM lung disease with the intent to
resubmit its MAA when clinical data from its ongoing global phase 3
study becomes available, the value of Insmed shares declined
significantly.
If you have suffered a loss in excess of $100,000 from
investment in Insmed securities purchased on or after March 18,
2013 and held through the revelation of negative information during
and/or at the end of the Class Period and would like to learn more
about this lawsuit and your ability to participate as a lead
plaintiff, without cost or obligation to you, please visit our
website at http://www.browerpiven.com/currentsecuritiescases.html.
You may also request more information by contacting Brower Piven
either by email at hoffman@browerpiven.com or by telephone at (410)
415-6616. Brower Piven also encourages anyone with information
regarding the Company’s conduct during the period in question to
contact the firm, including whistleblowers, former employees,
shareholders and others.
Attorneys at Brower Piven have extensive experience in
litigating securities and other class action cases and have been
advocating for the rights of shareholders since the 1980s. If you
choose to retain counsel, you may retain Brower Piven without
financial obligation or cost to you, or you may retain other
counsel of your choice. You need take no action at this time to be
a member of the class.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160726006532/en/
Brower Piven, A Professional CorporationCharles J. Piven,
410-415-66161925 Old Valley RoadStevenson, Maryland
21153hoffman@browerpiven.com
Insmed (NASDAQ:INSM)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024
Insmed (NASDAQ:INSM)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024